Botulinum toxin A 10U

PreclinicalSmall molecule

YYangHui

Botulinum toxin A 10U is one of 7 small molecule programs targeting Botulinum Toxin. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Botulinum ToxinUnknown status

Botulinum ToxinPreclinical

Unknown status

Competition

Competitive Landscape

6 competitors in Botulinum Toxin

#DrugCompanyPhaseTrials

Botox

RRevance Therapeutics, Inc.

Approved

44 2

Botulinum Toxin a

GSK

Phase 3

15 3

Botulinum Toxin

MMeshalkin Research Institute of Pathology of Circulation

Phase 3

12 4

Incobotulinum Toxin a

NNorthwestern University

Phase 1

1 5

Xeomin

MMerz Therapeutics GmbH

Preclinical

1 6

Botulinum toxin A 10U

YYangHui

Preclinical

1 7

Type a Botulinum Toxin

UUniversity Hospital, Rouen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Botulinum Toxin1 trial

Comparison of Different Botulinum Toxin A Injection Patterns in the Treatment of Blepharospasm

Unknown status·YYangHui·N/A·NCT02327728·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Botulinum toxin A 10U. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Botulinum toxin A 10U compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Botulinum toxin A 10U. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — YangHui company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: YYangHui

Botulinum toxin A 10U

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Botulinum Toxin1 trial

References

Drug Info

Quick Facts

Related News